Lei Zheng1,2, Chunbo Zhuang1,2, Xiaobei Wang2, Liang Ming1. 1. Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 2. Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract
BACKGROUND: Previous studies have demonstrated that dysfunctional regulatory T cells (Tregs) may be associated with Graves' disease (GD). In this study, we evaluated four serum Treg-associated miRNAs (miR-210, miR-182, miR-155, and miR-146a) expressions and assessed the potential of serum miRNAs as biomarkers of GD. METHODS: Foxp3 and serum miRNAs expressions both in GD patients and healthy controls were measured by RT-PCR. RESULTS: Serum miR-210 in GD patients was significantly higher than that of healthy controls (2.64-fold, P<.001); in contrast, miR-155 and miR-146a were lower (P<.001 and P=.008). No significant difference was found in miR-182. ROC curve analysis indicated that miR-210, miR-155, and miR-146a with the area under ROC (AUC) of 0.803 (70.0% sensitivity and 83.1% specificity), 0.796 (76.3% sensitivity and 76.9% specificity), and 0.736 (68.8% sensitivity and 73.8% specificity), respectively, could differentiate GD patients from healthy controls. Combination of three miRNAs yielded an AUC of 0.976 (91.3% sensitivity and 93.8% specificity) with 92.41% diagnostic efficiency. In addition, serum miR-210 and miR-155 in GD were associated with the extent of goiter. Three miRNAs levels were different by gender. Besides, serum miR-210 was positively correlated with free thyroxine (FT4) and thyrotrophin receptor antibody (TRAb) level. CONCLUSION: The serum levels of miR-210, miR-155, and miR-146a may be potential new markers for the diagnosis of GD and play important roles in GD pathogenesis.
BACKGROUND: Previous studies have demonstrated that dysfunctional regulatory T cells (Tregs) may be associated with Graves' disease (GD). In this study, we evaluated four serum Treg-associated miRNAs (miR-210, miR-182, miR-155, and miR-146a) expressions and assessed the potential of serum miRNAs as biomarkers of GD. METHODS:Foxp3 and serum miRNAs expressions both in GDpatients and healthy controls were measured by RT-PCR. RESULTS: Serum miR-210 in GDpatients was significantly higher than that of healthy controls (2.64-fold, P<.001); in contrast, miR-155 and miR-146a were lower (P<.001 and P=.008). No significant difference was found in miR-182. ROC curve analysis indicated that miR-210, miR-155, and miR-146a with the area under ROC (AUC) of 0.803 (70.0% sensitivity and 83.1% specificity), 0.796 (76.3% sensitivity and 76.9% specificity), and 0.736 (68.8% sensitivity and 73.8% specificity), respectively, could differentiate GDpatients from healthy controls. Combination of three miRNAs yielded an AUC of 0.976 (91.3% sensitivity and 93.8% specificity) with 92.41% diagnostic efficiency. In addition, serum miR-210 and miR-155 in GD were associated with the extent of goiter. Three miRNAs levels were different by gender. Besides, serum miR-210 was positively correlated with free thyroxine (FT4) and thyrotrophin receptor antibody (TRAb) level. CONCLUSION: The serum levels of miR-210, miR-155, and miR-146a may be potential new markers for the diagnosis of GD and play important roles in GD pathogenesis.
Authors: Eun-Jung Jung; Libero Santarpia; Juyeon Kim; Francisco J Esteva; Erica Moretti; Aman U Buzdar; Angelo Di Leo; Xiao-Feng Le; Robert C Bast; Soon-Tae Park; Lajos Pusztai; George A Calin Journal: Cancer Date: 2011-10-05 Impact factor: 6.860
Authors: Stephen S C Chim; Tristan K F Shing; Emily C W Hung; Tak-Yeung Leung; Tze-Kin Lau; Rossa W K Chiu; Y M Dennis Lo Journal: Clin Chem Date: 2008-01-24 Impact factor: 8.327
Authors: Li-Fan Lu; Mark P Boldin; Ashutosh Chaudhry; Ling-Li Lin; Konstantin D Taganov; Toshikatsu Hanada; Akihiko Yoshimura; David Baltimore; Alexander Y Rudensky Journal: Cell Date: 2010-09-17 Impact factor: 41.582